疟原虫对阿托伐醌/氯胍耐药性的临床意义:系统综述与荟萃分析
该系统综述评估阿托伐醌/氯胍治疗无并发症疟疾的临床疗效,并分析细胞色素b codon 268突变对治疗失败和再燃的影响。数据显示该药对恶性疟疗效为89%-98%,对间日疟为20%-26%;携带codon 268突变的患者再燃平均发生于第29天,比无突变者晚19天。
要点
- 阿托伐醌/氯胍治疗恶性疟原虫疟疾的疗效为89%-98%(27项研究,每项18至253例患者)。
- 间日疟原虫疟疾的疗效为20%-26%(1项研究,25例患者)。
- 携带细胞色素b codon 268突变的患者再燃平均发生于第29天(95%CI:22,35),比无突变者晚19天(95%CI:7,30)。
核心结论
- 证据提示阿托伐醌/氯胍治疗恶性疟原虫疟疾有效。
- 晚期治疗失败可能与细胞色素b codon 268突变相关,但近期动物模型证据提示这些突变可能不会在人群中传播。
- 早期治疗失败可能通过其他机制发生,需要进一步研究。
研究设计与样本
- 系统综述与荟萃分析,评估阿托伐醌/氯胍治疗无并发症疟疾的临床疗效,并基于已发表信息分析细胞色素b codon 268突变对治疗失败和再燃的影响。
主要发现
- 阿托伐醌/氯胍对恶性疟原虫疟疾的治疗疗效为89%-98%(来自27项研究,每项研究包括18至253例患者)。
- 阿托伐醌/氯胍对间日疟原虫疟疾的治疗疗效为20%-26%(来自1项研究,包括25例患者)。
- 体外恶性疟原虫阿托伐醌耐药表型为IC50值>28 nM。
- 病例报告分析预测,携带细胞色素b codon 268突变的患者再燃平均发生于第29天(95%CI:22,35),比无突变者晚19天(95%CI:7,30)。
关键数值与推荐
- 体外恶性疟原虫阿托伐醌耐药表型定义为IC50值>28 nM。
- 携带细胞色素b codon 268突变的患者再燃平均发生于第29天(95%CI:22,35),比无突变者晚19天(95%CI:7,30)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 早期治疗失败可能通过其他机制发生,需要进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atovaquone/proguanil, registered as Malarone®, is a fixed-dose combination recommended for first-line treatment of uncomplicated Plasmodium falciparum malaria in non-endemic countries and its prevention in travellers. Mutations in the cytochrome bc1 complex are causally associated with atovaquone resistance. METHODS: This systematic review assesses the clinical efficacy of atovaquone/proguanil treatment of uncomplicated malaria and examines the extent to which codon 268 mutation in cytochrome b influences treatment failure and recrudescence based on published information. RESULTS: Data suggest that atovaquone/proguanil treatment efficacy is 89%-98% for P. falciparum malaria (from 27 studies including between 18 and 253 patients in each case) and 20%-26% for Plasmodium vivax malaria (from 1 study including 25 patients). The in vitro P. falciparum phenotype of atovaquone resistance is an IC50 value >28 nM. Case report analyses predict that recrudescence in a patient presenting with parasites carrying cytochrome b codon 268 mutation will occur on average at day 29 (95% CI: 22, 35), 19 (95% CI: 7, 30) days longer than if the mutation is absent. CONCLUSIONS: Evidence suggests atovaquone/proguanil treatment for P. falciparum malaria is effective. Late treatment failure is likely to be associated with a codon 268 mutation in cytochrome b, though recent evidence from animal models suggests these mutations may not spread within the population. However, early treatment failure is likely to arise through alternative mechanisms, requiring further investigation.
引用
- Staines HM, Burrow R, Teo BH, et al. Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis. J Antimicrob Chemother. 2018. PMID: 29237012. doi:10.1093/jac/dkx431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。